Page 25 - 《中国药房》2021年10期

ministration-amendments-act-fdaaa-2007. [30] EMA. The EMA patient registries initiative[EB/OL].（2018-
[19] Office of the Law Revision Counsel of the U.S. House of 05-29）[2020-09-18]. https：//www.ema.europa.eu/en/docu-
Representatives. United States Code，title 21 §355：new ments/presentation/presentation-european-medicines-agen-
drugs[EB/OL]. [2020-09-20]. https：//uscode.house.gov/ cy-patient-registries-initiative-xavier-kurz_en.pdf.
view.xhtml?req=granuleid：USC-prelim-title21-section355& [31] EMA. Guideline on good pharmacovigilance practices
num=0&edition=prelim. （GVP）product- or population-specific considerations Ⅳ：
[20] Office of the Law Revision Counsel of the U.S. House of paediatric population[EB/OL].（2018-10-25）[2020-09-09].
Representatives. United States Code，title 21 §355c：re- https：//www.ema.europa.eu/en/documents/scientific-gui-
search into pediatric uses for drugs and biological pro- deline/guideline-good-pharmacovigilance-practices-gvp-
ducts[EB/OL]. [2020-09-20]. https：//uscode.house.gov/view. product-population-specific-considerations-iv_en-0.pdf.
xhtml?req=granuleid：USC-prelim-title21-section355c& [32] Pharma World. The new ICH E11（R1）on pediatric stu-
num=0&edition=prelim. dies[EB/OL]. （2017-10-17） [2021-05-09]. https：//www.
[21] FDA. Use of real-world evidence to support regulatory de- pharmaworldmagazine.com/new-ich-e11-r1-pediatric-stu-
cision-making for medical devices guidance for Industry dies/.
and Food and Drug Administration staff[EB/OL]. [2020-09- [33] ICH. Final concept paper ICH E6（R3）：guideline for good
20]. https：//www.fda.gov/media/99447/download.
clinical practice[EB/OL].（2018-12-18）[2020-09-20]. https：//
[22] FDA. Guidance document submitting documents using real- www.gmp-compliance.org/files/guidemgr/E6-R3_Final-
world data and real-world evidence to FDA for drugs and
ConceptPaper_2019_1117％20（1）.pdf.
biologics guidance for industry[EB/OL]. [2020-09-20].
[34] SWIFT B，JAIN L，WHITE C，et al. Innovation at the in-
https：//www.fda.gov/media/124795/download.
tersection of clinical trials and real-world data science to
[23] FDA，HHS. International Conference on Harmonisation：
advance patient care[J]. Clin Transl Sci，2018，11（5）：450-
guidance on E11 clinical investigation of medicinal pro-
460.
ducts in the pediatric population[N]. Fed Regist，2000，65
[35] Pediatric Trials Network. Annual review[EB/OL]. [2020-09-
（242）：78493-78494.
09]. https：//pediatrictrials.org/wp-content/uploads/2019/
[24] EMA. 10-year report to the European Commission[EB/
11/PTN_annual_review_20NOV2019_FINAL.pdf.
OL]. （2017-08-15） [2020-09-20]. https：//ec.europa.eu/
[36] Sisence. What is data standardization? [EB/OL]. [2020-09-
health/sites/health/files/files/paediatrics/docs/paediatrics_
20]. https：//www.sisense.com/glossary/data-standardiza-
10_years_ema_technical_report.pdf.
tion/.
[25] LEHMANN B. Regulation（EC）No. 1901/2006 on medici-
[37] PETER O D. EU bids to overcome data fragmentation in
nal products for paediatric use & clinical research in vul-
pursuit of real-world evidence[J]. Applied Clinical Trials，
nerable populations[J]. Child Adolesc Psychiatry Ment
2017，26（8）：7-8.
Health，2008，2（1）：37.
[38] FDA. Biomarker qualification review for total kidney vo-
[26] EMA. Paediatric regulation[EB/OL].[2020-09-20]. https：//
lume[EB/OL].（2018-05-30）[2020-09-09]. https：//www.
www.ema.europa.eu/en/human-regulatory/overview/paedi-
fda.gov/media/93143/download.
atric-medicines/paediatric-regulation.
[27] EMA. European network of paediatric research at the [39] MICHEEL C M，BALL J R. Evaluation of biomarkers and
European Medicines Agency[EB/OL]. [2020-09-09]. https：// surrogate endpoints in chronic disease[M]. Washington
www.ema.europa.eu/en/documents/leaflet/european-net- （DC）：National Academies Press（US），2010：52-65.
work-paediatric-research-european-medicines-agency_en. [40] WAGNER J A，BALL J R. Implications of the Institute of
pdf. Medicine report：evaluation of biomarkers and surrogate
[28] EMA. Paediatric investigation plans：questions and an- endpoints in chronic disease[J]. Clin Pharmacol Ther，
swers [EB/OL].[2019-09-09]. https：//www.ema.europa.eu/ 2015，98（1）：12-15.
en/human-regulatory/research-development/paediatric- [41] BEGHETTI M. Paediatric pulmonary hypertension：moni-
medicines/paediatric-investigation-plans/paediatric-investi- toring progress and identifying unmet needs[J]. Eur Respir
gation-plans-questions-answers#1.-applying-for-a-pip，-waiv- Rev，2009，18（111）：18-23.
er-or-deferral-section. [42] BERGER R M，BEGHETTI M，HUMPL T，et al. Clinical
[29] RWE Navigator. Real-life data in drug development[EB/ features of paediatric pulmonary hypertension：a registry
OL]. [2021-05-09]. https：//rwe-navigator.eu/homepage/ study[J]. Lancet，2012，379（9815）：537-546.
what-is-the-imi-getreal-project/. [43] DREYER N A. Advancing a framework for regulatory use

中国药房 2021年第32卷第10期 China Pharmacy 2021 Vol. 32 No. 10 ·1171 ·